高龄大血管闭塞卒中血管内取栓的成本效益
本研究基于澳大利亚和新西兰4个综合卒中中心的回顾性队列及国际卒中灌注影像登记数据,构建Markov模型评估80岁及以上大血管闭塞卒中患者血管内取栓(EVT)与标准药物治疗的成本效益。倾向评分匹配后EVT组90天良好功能结局(mRS≤2)比例为37%对18%,模型显示EVT每例净成本AU$3,399、增益0.97 QALYs,ICER为每QALY AU$3,508,具有成本效益。
要点
- 80岁及以上LVO卒中患者EVT较标准药物治疗可提高90天良好功能结局比例。
- EVT每例净成本AU$3,399,ICER为每QALY AU$3,508,远低于澳大利亚支付意愿阈值。
- 敏感性分析中100%模拟ICER低于AU$50,000/QALY,支持向高龄患者提供EVT。
核心结论
- 对于80岁及以上大血管闭塞卒中患者,EVT相对于标准药物治疗具有成本效益并可带来显著临床获益。
研究设计与样本
- 采用澳大利亚医疗保健视角的模型化成本效益研究,基于回顾性队列(4个综合卒中中心)及国际卒中灌注影像登记数据。
- 纳入548例年龄≥80岁患者(平均85.1岁,女性296例[54%])进行倾向评分匹配分析。
- 以倾向评分匹配后90天mRS分布构建决策分析Markov模型,成本和效用数据取自已发表来源。
主要发现
- 倾向评分匹配后,EVT组良好结局(mRS≤2)比例为37%,标准治疗组为18%。
- 基于1万例假设样本的模型分析,EVT估计在15年内避免471例死亡。
- 每例患者EVT带来0.95年生命增益和0.97 QALYs增益,净成本为AU$3,399。
关键数值与推荐
- 主要结局为增量成本效果比(ICER),以每获得QALY的成本表示。
- EVT的ICER为每QALY AU$3,508,从医疗保健视角具有成本效益。
- 敏感性分析中100%模拟ICER低于澳大利亚常用支付意愿阈值AU$50,000/QALY。
临床怎么用
- 研究结果支持向80岁及以上大血管闭塞卒中患者提供血管内取栓治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Endovascular thrombectomy (EVT) is associated with considerable clinical benefits for patients after large vessel occlusion (LVO) stroke. However, EVT remains underused in Australia, particularly among the very elderly (aged ≥80 years). The aim of this study was to evaluate the cost-effectiveness and clinical effectiveness of EVT vs standard medical management among very elderly patients using real-world, observational data. METHODS: A modeled cost-effectiveness study was conducted from the Australian health care perspective. Data from a retrospective cohort of patients aged 80 years or older treated with EVT at 4 comprehensive stroke centers across Australia and New Zealand, as well as data from the International Stroke Perfusion Imaging Registry, were used to inform our economic analyses. The distribution of 90-day modified Rankin Scale (mRS) outcomes after propensity score matching was used to inform a decision-analytic Markov model. Costs and utility data for calculating quality-adjusted life years (QALYs) were drawn from published sources. The primary outcome of this analysis was the incremental cost-effectiveness ratio (ICER) in terms of cost per QALY gained for EVT compared with medical management. Uncertainty was evaluated with deterministic and probabilistic sensitivity analyses. RESULTS: A total of 548 patients (mean age 85.1 years and 296 women [54%]) were included to inform the propensity score matching analysis. After propensity score matching, the proportion of patients with favorable (mRS score ≤2) outcomes was higher for EVT vs standard care (37% vs 18%). Based on the modeled cost-effectiveness analysis comprising a hypothetical sample of 10,000 patients, EVT was estimated to prevent 471 deaths over a period of 15 years. On a per-patient basis, EVT was associated with a gain of 0.95 years of life and 0.97 QALYs at a net cost of AU$3,399. That is, from a health care perspective, EVT is cost-effective for very elderly patients with LVO stroke (ICER: $3,508 per QALY). Sensitivity analyses supported the robustness of the model, with 100% of simulated ICERs falling below the commonly accepted Australian willingness-to-pay threshold of AU$50,000 per QALY. DISCUSSION: EVT is cost-effective and associated with considerable clinical benefits relative to standard medical management for very elderly patients with LVO stroke. Our findings support the provision of EVT to the very elderly.
引用
- Lee P, Wu T, Chen C, et al. Cost-Effectiveness of Endovascular Thrombectomy in Large Vessel Occlusion Stroke for the Very Elderly. Neurology. 2025. PMID: 41043095. doi:10.1212/WNL.0000000000214079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。